❝
Good Morning! This exclusive edition of The Funding Letter comes to you from our headquarters in New York City. 🔥New Sales Gigs from Apollo below!
Hit the Gong 🎉
Source: @sales_bant_er
Daily Deals 💸
🌎 Americas
ImmunityBio is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. View on: LinkedIn.com | Sales Navigator.
New Funding Raised: $270M, Post-IPO Equity + $200M, Post-IPO Debt
Round Investors: NantCapital (lead)
🚀Growth Focus: Support its ongoing operations and pre-commercialization activities through the anticipated potential FDA approval of Anktiva for BCG-unresponsive bladder cancer.
Press: Business Wire, ImmunityBio News
HQ: San Diego, CA
Industry: Biotechnology Research
Employee Count: 540